Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
GRN
REST API REST API
Homo sapiens
GRN is differentially expressed in 324 experiments: 146 organism parts: lung, placenta, ... (144 more);, 201 disease states: normal, control, ... (199 more);, 126 cell types 376 cell lines 49 compound treatments and 73 other conditions.
Synonyms PGRN, PCDGF
Orthologs ENSCING00000012906 (Ciona intestinalis)   grna (Danio rerio)   Grn (Mus musculus)   GRN (Bos taurus)   grnb (Danio rerio)   Grn (Rattus norvegicus)   grn (Xenopus laevis)   GRN (Canis familiaris)   (Compare orthologs)
Gene Ontology Term extracellular space, growth factor activity, extracellular region, cytokine activity, signal transduction, mitochondrion, blastocyst hatching, positive regulation of epithelial cell proliferation, embryo implantation
InterPro Term Granulin
UniProt Accession Q9H8S1, P28799
Gene-Disease Assocation FRONTOTEMPORAL LOBAR DEGENERATION WITH TDP43 INCLUSIONS, GRN-RELATED
Search EB-eye ENSG00000030582
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-15765, E-GEOD-803, E-GEOD-6573, E-GEOD-1577, E-GEOD-7540, ... (27 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-17482, E-GEOD-5258, E-GEOD-4525, E-MEXP-1006, E-GEOD-19639, ... (43 experiments)

Factor Value U/D Experiments
HL-60
1
3
E-MTAB-37, E-GEOD-24147, E-GEOD-5258, E-GEOD-96
MOLT4
2
E-MTAB-37, E-MTAB-62
SW480
2
E-MEXP-1014, E-GEOD-2509
primary culture
2
E-GEOD-1657, E-GEOD-2450
K562
1
2
E-MTAB-37, E-GEOD-24147, E-GEOD-96
PC3
1
2
E-GEOD-14464, E-MEXP-2034, E-GEOD-5258
370 more value(s).


Cell type

studied in E-GEOD-492, E-GEOD-20193, E-GEOD-21668, E-GEOD-3920, E-GEOD-20677, ... (61 experiments)

Factor Value U/D Experiments
dendritic cell
2
E-GEOD-3982, E-GEOD-360
embryonic stem cell
2
E-MEXP-930, E-GEOD-2248
human embryonic stem cell
2
E-GEOD-20033, E-GEOD-18265
neutrophil
2
E-GEOD-3982, E-GEOD-12662
fibroblast
1
2
E-GEOD-3920, E-GEOD-3204, E-GEOD-26672
CD14+ monocyte
1
2
E-AFMX-5, E-MEXP-1600, E-TABM-145
120 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-15960, E-GEOD-2466, E-GEOD-1577, E-TABM-15, ... (65 experiments)

Factor Value U/D Experiments
control
5
E-GEOD-21912, E-GEOD-8121, E-GEOD-16363, E-GEOD-20168, E-GEOD-20295 ... (5 experiments)
dermatomyositis
3
E-MTAB-62, E-GEOD-5370, E-GEOD-1551
colon carcinoma
2
E-MTAB-62, E-MTAB-37
prostate carcinoma
2
E-MTAB-62, E-MEXP-2034
Duchenne muscular dystrophy
1
2
E-GEOD-3307, E-GEOD-1004, E-GEOD-1007
liver carcinoma
1
E-MTAB-37
195 more value(s).


Compound treatment

studied in E-GEOD-7400, E-GEOD-5741, E-TABM-782, E-GEOD-697, E-GEOD-3720, ... (30 experiments)

Factor Value U/D Experiments
dimethyl sulfoxide
2
E-GEOD-6932, E-GEOD-5824
lipopolysaccharide
2
E-MEXP-1958, E-GEOD-3720
HMB-PP (phosphoantigen)
1
E-MEXP-1601
phenol
1
E-GEOD-6907
ZMYM2/FGFR1
1
E-GEOD-15811
unknown
1
E-GEOD-7307
43 more value(s).


Agent

studied in E-GEOD-19519

Factor Value U/D Experiments
thapsigargin
1
1
E-GEOD-19519
tunicamycin
1
1
E-GEOD-19519


Biopsy tissue
studied in E-GEOD-5851

BioSourceProvider
studied in E-GEOD-19466, E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Cancer site
studied in E-GEOD-4271

Cell treatment
studied in E-MEXP-1192

Cellular component
studied in E-GEOD-1400

Chromosomal aberration
studied in E-TABM-125

Clinical history
studied in E-GEOD-22097, E-TABM-234, E-GEOD-19743, E-GEOD-7967, E-TABM-125, ... (9 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-GEOD-6710, E-GEOD-1140, E-MEXP-1251, ... (12 experiments)

Clinical treatment
studied in E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

development stage
studied in E-GEOD-22601

Developmental stage
studied in E-GEOD-5999, E-GEOD-1614, E-GEOD-20033, E-GEOD-4667, E-MTAB-62 ... (5 experiments)

dfs time (months)
studied in E-GEOD-21653

Disease staging
studied in E-GEOD-89, E-GEOD-19743, E-GEOD-7788, E-GEOD-3325, E-GEOD-2509, ... (9 experiments)

Environmental stress
studied in E-GEOD-1518, E-GEOD-3720

Er
studied in E-GEOD-20194, E-GEOD-16716

Estrogen receptor status
studied in E-GEOD-6532

Ethnic group
studied in E-GEOD-20194, E-GEOD-16716

Ethnicity
studied in E-GEOD-16363

family id
studied in E-GEOD-19519

Genetic modification
studied in E-GEOD-8023, E-MTAB-73, E-MEXP-1482, E-GEOD-7578, E-GEOD-17385, ... (8 experiments)

Genotype
studied in E-GEOD-1045, E-GEOD-2466, E-GEOD-17476, E-GEOD-22593, E-TABM-601, ... (13 experiments)

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-GEOD-6432, E-GEOD-5681, E-GEOD-12773, E-GEOD-20540, E-GEOD-20504, ... (9 experiments)

Her2 fish
studied in E-GEOD-20194, E-GEOD-16716

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-234, E-GEOD-21653, E-TABM-276, E-GEOD-20194, E-GEOD-16716 ... (5 experiments)

Individual
studied in E-TABM-325, E-MTAB-197, E-GEOD-2466, E-MEXP-2069, E-GEOD-1926, ... (35 experiments)

Infection
studied in E-MEXP-1274, E-GEOD-12108, E-GEOD-12254, E-GEOD-9723, E-MEXP-561, ... (6 experiments)

Injury
studied in E-GEOD-19743

Irradiate
studied in E-GEOD-1977, E-TABM-321

Karyotype
studied in E-GEOD-22056

Labeling
studied in E-LGCL-5

Light
studied in E-GEOD-1725

Material type
studied in E-MEXP-455, E-MEXP-958

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

Molecular subtype
studied in E-GEOD-21653

Nbefore
studied in E-GEOD-20194, E-GEOD-16716

Observation
studied in E-TABM-276

organ
studied in E-GEOD-24283

Organism
studied in E-GEOD-7540, E-GEOD-1801

Organism status
studied in E-GEOD-19188

Performer
studied in E-LGCL-5

Phase
studied in E-GEOD-4888

Phenotype
studied in E-GEOD-19703, E-GEOD-6434, E-GEOD-1657, E-GEOD-17636, E-GEOD-4600, ... (6 experiments)

Population
studied in E-GEOD-4922

Progesterone receptor status
studied in E-GEOD-6532

Protocol type
studied in E-GEOD-22097, E-GEOD-3254, E-GEOD-21837, E-GEOD-1880, E-GEOD-19445, ... (7 experiments)

Replicate
studied in E-GEOD-10797, E-GEOD-18791

RNAi
studied in E-MEXP-2115, E-GEOD-12438, E-MEXP-1509, E-GEOD-1676, E-MEXP-101, ... (8 experiments)

Sample preparation
studied in E-GEOD-16728

Sample type
studied in E-TABM-783

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-19743, E-MEXP-70, E-GEOD-17400, E-GEOD-18995

Sex
studied in E-GEOD-1643, E-GEOD-19069, E-GEOD-2466, E-GEOD-7307

Stimulation
studied in E-GEOD-20114, E-GEOD-11428

Strain or line
studied in E-TABM-125

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-19188

targeted_cell_type
studied in E-MEXP-70

Tbefore
studied in E-GEOD-20194, E-GEOD-16716

Test result
studied in E-TABM-276

Treatment
studied in E-GEOD-16837, E-GEOD-19246, E-GEOD-13818, E-GEOD-19815, E-GEOD-15799 ... (5 experiments)

Treatment code
studied in E-GEOD-20194, E-GEOD-16716

Tumor grading
studied in E-GEOD-4290

Processing time: 0.358 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM